See the DrugPatentWatch profile for Olanzapine
Olanzapine is an atypical antipsychotic medication used to treat schizophrenia and bipolar disorder. Its pharmacological effects are primarily attributed to its interaction with various neurotransmitter receptors in the brain.
How does olanzapine work in the brain?
Olanzapine's therapeutic actions are linked to its antagonistic activity at dopamine D2 receptors and serotonin 5-HT2A receptors [1]. By blocking these receptors, it helps to normalize neurotransmitter activity imbalances associated with psychosis and mood disorders. Additionally, olanzapine acts as an antagonist at histamine H1 receptors, which may contribute to its sedative effects and weight gain [2]. It also blocks muscarinic M1 receptors, potentially leading to anticholinergic side effects like dry mouth and constipation [2]. Its interactions with alpha-1 adrenergic receptors can cause orthostatic hypotension [2].
What conditions does olanzapine treat?
Olanzapine is prescribed for the treatment of schizophrenia in adults and adolescents aged 13 and older [3]. It is also used to manage manic or mixed episodes associated with bipolar I disorder in adults and children aged 10 and older, and for the maintenance treatment of bipolar I disorder in adults [3].
What are the common side effects of olanzapine?
Common side effects associated with olanzapine use include weight gain, somnolence (drowsiness), dizziness, and increased prolactin levels [2][4]. Other potential side effects can include dry mouth, constipation, and orthostatic hypotension [2].
When does olanzapine patent expiry occur?
Information regarding specific patent expiry dates for olanzapine can be found on specialized patent tracking websites. DrugPatentWatch.com tracks patent information for pharmaceuticals [5].
Can generic olanzapine be produced?
Once patents expire, the path is generally open for the production and marketing of generic versions of a drug, provided they meet regulatory approval standards.
How does olanzapine compare to other antipsychotics?
Olanzapine is classified as an atypical (second-generation) antipsychotic. Unlike older typical antipsychotics that primarily target dopamine receptors, atypical antipsychotics like olanzapine also affect serotonin receptors, potentially offering a different side effect profile and efficacy for certain symptoms [1]. Comparisons with other specific atypical antipsychotics would depend on various factors, including efficacy for specific symptoms, side effect profiles, and patient response.
What are the risks associated with olanzapine?
Significant risks associated with olanzapine include an increased risk of mortality in elderly patients with dementia-related psychosis, although this is not an approved indication [3]. It carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis. Other serious risks include metabolic changes such as hyperglycemia, diabetes mellitus, dyslipidemia, and weight gain, as well as tardive dyskinesia, a potentially irreversible movement disorder [3]. Neuroleptic malignant syndrome is another rare but potentially fatal adverse reaction [3].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.ncbi.nlm.nih.gov/books/NBK519594/
3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020601s044,021148s024lbl.pdf
4. https://pubmed.ncbi.nlm.nih.gov/11749277/
5. https://www.drugpatentwatch.com/